← Back to Search

Procedure

Ablative Therapy for Oligoprogressive Cancer (VALOROUS Trial)

N/A
Recruiting
Led By Xiao Zhao, MD
Research Sponsored by University of California, Davis
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥18 years at time of consent.
≤ 5 progressing or new metastatic lesions.
Must not have
History of treatment related toxicities that limit or prohibit application of locally ablative therapies.
Progressing intracranial lesions.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months from the first day of ablative local therapy
Awards & highlights
No Placebo-Only Group

Summary

This trial studies the effectiveness of adding localized treatments to systemic therapy for solid tumors that have not spread widely. The results will measure how long treatment lasts.

Who is the study for?
Adults over 18 with certain cancers (like breast, gynecological, head and neck, sarcomas) who have up to 5 new or worsening metastatic lesions. They must be on systemic therapy they can continue post-treatment and have seen benefits from it for at least 3 months. Not eligible if they have progressing brain tumors or health issues that rule out local therapies.
What is being tested?
The VALOROUS trial is testing whether adding local ablative treatments (like radiation) to ongoing systemic cancer therapy helps control the disease better in patients whose cancer has started to progress again but only in a limited number of spots.
What are the potential side effects?
While specific side effects are not listed here, generally, local ablative therapies like radiation may cause skin irritation, fatigue, mild pain or discomfort at the treatment site. The exact side effects depend on the area being treated.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have 5 or fewer new or growing cancer spots.
Select...
My cancer is confirmed to be in the urinary-genital area.
Select...
I have cancer in my head or neck.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have side effects from past treatments that prevent me from getting certain local therapies.
Select...
My brain tumor is getting worse.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months from the first day of ablative local therapy
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months from the first day of ablative local therapy for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Disease control
Secondary study objectives
Grade ≥ 3 adverse events
Median overall survival
Time to treatment failure

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Ablative local therapyExperimental Treatment1 Intervention
Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy

Find a Location

Who is running the clinical trial?

University of California, DavisLead Sponsor
943 Previous Clinical Trials
4,755,438 Total Patients Enrolled
2 Trials studying Sarcoma
8 Patients Enrolled for Sarcoma
National Cancer Institute (NCI)NIH
13,928 Previous Clinical Trials
41,017,810 Total Patients Enrolled
459 Trials studying Sarcoma
229,403 Patients Enrolled for Sarcoma
Xiao Zhao, MDPrincipal InvestigatorUniversity of California, Davis
~115 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top